MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 413450 | Name: Dalazatide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Dalazatide is a first-in-class investigational drug designed to selectively target cells that cause autoimmune diseases such as lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, type 1 diabetes, and multiple sclerosis (MS).

Chemical Structure

Dalazatide
Dalazatide
CAS#1081110-69-1

Theoretical Analysis

MedKoo Cat#: 413450

Name: Dalazatide

CAS#: 1081110-69-1

Chemical Formula: C184H296N57O55PS7

Exact Mass: 4438.9900

Molecular Weight: 4442.13

Elemental Analysis: C, 49.75; H, 6.72; N, 17.97; O, 19.81; P, 0.70; S, 5.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Dalazatide; SHK186; SHK 186; SHK-186
IUPAC/Chemical Name
o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide
InChi Key
GORAHSAIYZMTHZ-LBFSFEBVSA-N
InChi Code
InChI=1S/C184H296N57O55PS7/c1-14-94(5)139-172(283)223-124(79-138(254)255)162(273)238-144(100(11)249)176(287)236-140(95(6)15-2)178(289)240-68-33-46-135(240)171(282)217-112(41-24-28-61-187)152(263)224-125(82-242)163(274)212-116(45-32-66-204-182(197)198)153(264)229-134-91-304-303-89-132-168(279)214-114(43-30-64-202-180(193)194)148(259)210-113(42-25-29-62-188)156(267)237-143(99(10)248)175(286)232-130(147(258)206-81-137(253)234-141(97(8)246)174(285)227-129(145(192)256)86-299-301-90-133(169(280)235-139)231-166(277)128(85-245)233-179(290)184(58-34-67-205-183(199)200,295-71-70-294-69-63-189)241(101(12)250)177(288)109(190)74-104-49-53-108(54-50-104)296-297(291,292)293)87-300-302-88-131(228-154(265)117(55-56-136(191)252)215-158(269)120(75-102-35-18-16-19-36-102)218-146(257)96(7)208-173(284)142(98(9)247)239-170(134)281)167(278)213-111(40-23-27-60-186)150(261)222-123(78-106-80-201-92-207-106)161(272)226-126(83-243)164(275)216-118(57-72-298-13)155(266)209-110(39-22-26-59-185)149(260)220-122(77-105-47-51-107(251)52-48-105)159(270)211-115(44-31-65-203-181(195)196)151(262)219-119(73-93(3)4)157(268)225-127(84-244)165(276)221-121(160(271)230-132)76-103-37-20-17-21-38-103/h16-21,35-38,47-54,80,92-100,109-135,139-144,242-249,251H,14-15,22-34,39-46,55-79,81-91,185-190H2,1-13H3,(H2,191,252)(H2,192,256)(H,201,207)(H,206,258)(H,208,284)(H,209,266)(H,210,259)(H,211,270)(H,212,274)(H,213,278)(H,214,279)(H,215,269)(H,216,275)(H,217,282)(H,218,257)(H,219,262)(H,220,260)(H,221,276)(H,222,261)(H,223,283)(H,224,263)(H,225,268)(H,226,272)(H,227,285)(H,228,265)(H,229,264)(H,230,271)(H,231,277)(H,232,286)(H,233,290)(H,234,253)(H,235,280)(H,236,287)(H,237,267)(H,238,273)(H,239,281)(H,254,255)(H4,193,194,202)(H4,195,196,203)(H4,197,198,204)(H4,199,200,205)(H2,291,292,293)/t94-,95-,96-,97+,98+,99+,100+,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130?,131-,132-,133-,134-,135-,139-,140-,141-,142-,143-,144-,184+/m0/s1 Download InChIKey GORAHSAIYZMTHZ-LBFSFEBVSA-N Search the web for this InChIKey Smiles CC[C@H](C)[C@@H]1NC(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)C2CSSC[C@@H]3NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](Cc5ccccc5)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc6ccc(O)cc6)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](Cc7c[nH]cn7)NC(=O)[C@H](CCCCN)NC3=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC1=O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@@](CCCNC(=N)N)(OCCOCCN)N(C(=O)C)C(=O)[C@@H](N)Cc9ccc(OP(=O)(O)O)cc9 Download Data Source for o-PHOSPHONO-L-Tyrosyl-2-(2-(2-aminoethoxy)ethoxy)acetyl(potassium channel toxin kappa-stichotoxin-shela stoichactis helianthus (caribbean sea anemone)) peptidamide List Acronyms FDA SRS (FDA Substance Registration System) Click on 1081110-69-1's icon or row to pin it open.
SMILES Code
CC[C@@H]([C@@H]1NC([C@@H](NC([C@@H](NC([C@@](OCCOCCN)(N(C([C@H](Cc2ccc(OP(O)(O)=O)cc2)N)=O)C(C)=O)CCCNC(N)=N)=O)CO)=O)CSSC[C@@H](C(N)=O)NC([C@H]([C@H](O)C)NC(CNC(C3CSSC[C@@H]4NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H]5CCCN5C([C@H]([C@H](CC)C)NC([C@H]([C@H](O)C)NC([C@@H](NC1=O)CC(O)=O)=O)=O)=O)=O)CCCCN)=O)CO)=O)CCCNC(N)=N)=O)CSSC[C@@H](C(NC(C(NC(C(N[C@H](C(N3)=O)[C@H](O)C)=O)CCCCN)=O)CCCNC(N)=N)=O)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC4=O)CCCCN)=O)Cc6nc[nH]c6)=O)CO)=O)CCSC)=O)CCCCN)=O)Cc7ccc(O)cc7)=O)CCCNC(N)=N)=O)CC(C)C)=O)CO)=O)Cc8ccccc8)=O)=O)=O)C)=O)Cc9ccccc9)=O)CCC(N)=O)=O)=O)=O)=O)=O)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 100.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 4,442.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tarcha EJ, Olsen CM, Probst P, Peckham D, Muñoz-Elías EJ, Kruger JG, Iadonato SP. Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial. PLoS One. 2017 Jul 19;12(7):e0180762. doi: 10.1371/journal.pone.0180762. PMID: 28723914; PMCID: PMC5516987. 2: Prentis PJ, Pavasovic A, Norton RS. Sea Anemones: Quiet Achievers in the Field of Peptide Toxins. Toxins (Basel). 2018 Jan 8;10(1):36. doi: 10.3390/toxins10010036. PMID: 29316700; PMCID: PMC5793123. 3: Tajti G, Wai DCC, Panyi G, Norton RS. The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides. Biochem Pharmacol. 2020 Nov;181:114146. doi: 10.1016/j.bcp.2020.114146. Epub 2020 Jul 10. PMID: 32653588. 4: Liao Q, Feng Y, Yang B, Lee SM. Cnidarian peptide neurotoxins: a new source of various ion channel modulators or blockers against central nervous systems disease. Drug Discov Today. 2019 Jan;24(1):189-197. doi: 10.1016/j.drudis.2018.08.011. Epub 2018 Aug 27. PMID: 30165198. 5: Tanner MR, Pennington MW, Chauhan SS, Laragione T, Gulko PS, Beeton C. KCa1.1 and Kv1.3 channels regulate the interactions between fibroblast-like synoviocytes and T lymphocytes during rheumatoid arthritis. Arthritis Res Ther. 2019 Jan 7;21(1):6. doi: 10.1186/s13075-018-1783-9. PMID: 30612588; PMCID: PMC6322314.